NYSE: DOCHealthpeak Properties

    Healthpeak Properties Q3 2026 Results: Net Income $17.1 Million on Revenue of $821 Million

    • US stocks
    • Earnings
    • Real Estate
    A US one-dollar banknote standing upright against a white brick wall on a glossy surface
    NeONBRAND neonbrand, via Wikimedia Commons (CC0). Illustrative image.

    Healthpeak Properties (NYSE: DOC) reported results for the quarter ended 30 Sep 2026, and it said on 2 Nov 2026 that GAAP revenue was $820.9 million and GAAP net income applicable to common shares was $17.1 million. Diluted EPS was $0.02 (GAAP), and FFO as Adjusted, a company-defined non-GAAP measure, was $0.44 per share.

    Key highlights

    • Revenue (GAAP): $820.9 million, up 16.3% YoY
    • Net income (GAAP): $17.1 million, against a loss of $117.3 million a year earlier
    • Diluted EPS (GAAP): $0.02, against a loss of $0.17 a year earlier
    • FFO as Adjusted per share (company-defined, non-GAAP): $0.44, against $0.46 a year earlier
    • Net income margin (GAAP): 2.1% of revenue, 18.7 percentage points higher than a year earlier

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ3 2026Q3 2025YoY
    Revenue820.9705.9+16.3%
    17.1-117.3n/a
    Diluted EPS ($)0.02-0.17n/a

    Figures are in $ million except EPS; YoY compares with Q3 2025. Q3 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are the release's own comparatives, not cross-checked against SEC XBRL data. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    The table shows GAAP revenue of $820.9 million, up 16.3% from $705.9 million a year earlier. GAAP net income was $17.1 million, against a net loss of $117.3 million a year earlier.

    Net income was 2.1% of revenue, against a negative 16.6% a year earlier, a difference of 18.7 percentage points. Blacklitt computed these margins from the table.

    Adjusted figures exclude the items the company names

    FFO as Adjusted, a company-defined non-GAAP measure, was $0.44 per share against $0.46 a year earlier, and Diluted Nareit FFO was $0.43 per share against $0.45. The company describes Nareit FFO and FFO as Adjusted as supplemental non-GAAP measures.

    Full-year EPS outlook lowered and FFO outlook raised

    The company now expects full-year 2026 diluted EPS (GAAP) of $0.39 to $0.41, down from $0.48 to $0.52 as of 4 Aug 2026. The company attributes the cut mainly to depreciation and amortization tied to senior housing acquisitions that Janus Living closed, and notes that this depreciation is excluded from Nareit FFO and FFO as Adjusted.

    The company raised its 2026 FFO as Adjusted per share outlook to $1.76 to $1.78, from $1.73 to $1.77, and its Total Same-Store Cash (Adjusted) NOI growth outlook to 0.5% to 2.0%, from 0% to 1.5%.

    Acquisitions and a new $500 million term loan

    Janus Living, a senior housing REIT that Healthpeak owns 69% of, closed $1.75 billion of senior housing acquisitions in the quarter and about $370 million from quarter end through 30 Oct 2026. Healthpeak acquired, or is under contract to acquire, four life science buildings of about 510,000 square feet for about $233 million.

    In October 2026 Healthpeak set up a new $500 million unsecured delayed-draw term loan, maturing in October 2030, and it was undrawn when it closed. As of 30 Oct 2026 Healthpeak had $3.8 billion of liquidity.

    Inference

    Diluted weighted average shares for the Diluted Nareit FFO calculation were 703.98 million in the quarter, against 709.51 million a year earlier. Healthpeak's board declared monthly dividends of $0.10167 per share for October, November and December 2026, which annualizes to $1.22 per share, with record dates of 19 Oct, 13 Nov and 18 Dec 2026 and payment dates of 30 Oct, 25 Nov and 30 Dec 2026.

    The release does not give a full-year 2026 net income figure in dollars, or stand-alone GAAP results for Janus Living.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Latest posts